Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Warburg Pincus invests $75mm in Inspire Pharmaceuticals

Executive Summary

Inspire Pharmaceuticals, which is developing compounds for dry eye, cystic fibrosis, and allergic rhinitis, sold $75mm of its preferred stock to Warburg Pincus. The private equity firm may exchange a preferred share for 100 common shares at $5.35 each (the average price at deal announcement was $5.76). A Warburg managing director has joined the company's board. Inspire will use the money to support the launch of newly approved AzaSite for pink eye (licensed from InSite Vision in February) and to develop its Phase III candidates. NOTE: An Inspire quarterly filing reveals that 140k Series A preferred shares were exchanged for 14mm common shares resulting in net proceeds of $73.6mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies